Overview

Third Dose of COVID-19 Vaccine in LTCF Residents

Status:
Not yet recruiting

Trial end date:
2022-04-15

Target enrollment:

Participant gender:

Summary

This study is a multi-centre, blinded, randomized controlled trial. LTCF residents ≥65 years who have had two doses of mRNA-1273 vaccine will be randomized to vaccination with a third dose of mRNA-1273 vaccine or to vaccination with a control (Prevnar-13 vaccine).

Phase:

Phase 4

Details

Lead Sponsor:

Mark Loeb

Treatments:

Heptavalent Pneumococcal Conjugate Vaccine
Vaccines